13:43:07 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-28 Årsstämma 2024
2024-05-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 X-dag ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 X-dag ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 X-dag ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 X-dag ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst verksamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2024-05-28 11:00:00

Ziccum partners with Dagens Industri, the largest Nordic business paper, to improve shareholders’ access to news updates and raise broader awareness of its continuous scientific and commercial progress.

Ziccum AB has signed a partnership with the Investor Relations arm of Dagens Industri, joining a select group of Nordic SMEs in a bid to ensure timely, efficient, and professional dissemination of its increasing information flow. The scope includes interviews in text and video format as well as company coverage in smaller and larger features in the main DI paper.

Operating at the cutting edge of science, developing a disruptive technology enabling new and much improved biopharmaceuticals and continuously gaining increased recognition from international Pharma & Biotech industry, Ziccum sees the need to keep its loyal regional investor base well-apprised by providing systematic and accessible updates on its progress. Ziccum could not ask for a better partner than Dagens Industri, an institution of business reporting among the Nordic investment community for decades.

Ziccum’s CEO, Ann Gidner: “Now that Dagens Industri are selecting a few smaller Swedish listed companies to be well featured, we are delighted to be included and it is perfect timing with our need for better visibility in investors’ circles”.

About Dagens Industri:

Dagens Industri was founded in 1976 and is currently owned by the Swedish media group Bonnier AB. DI’s online edition, di.se, has been consistently voted as Sweden’s “best economics online site” for 20 years (from 1999 to 2019) in a competition held by the PR firm Hallvarsson & Halvarsson.